Evogene (EVGN) Director Leon Recanati Receives Option Grant

What Happened
Leon Recanati, a director of Evogene Ltd. (EVGN), was granted 2,500 stock options on September 4, 2026. The grant was reported as a derivative award (transaction code A) with no cash paid at grant (acquisition price $0). The options carry an exercise price of NIS 1.75 per share (reported equivalent $0.58 per share using the Bank of Israel rate on the grant date).

Key Details

• Transaction date: September 4, 2026; Form 4 filed September 30, 2026 (filed after the typical two-business-day reporting window).
• Security: Options to purchase 2,500 ordinary shares (derivative). Acquisition price at grant: $0.
• Exercise price: NIS 1.75 per share = $0.58 per share (footnote conversion).
• Vesting: 25% per quarter beginning September 4, 2026; fully vested on September 4, 2027.
• Source/plan: Granted under Evogene’s 2021 Share Incentive Plan.
• Holdings after transaction: Not specified in the provided rows of the filing.
• Footnotes of interest: F1 notes an informational row with no transaction; F2 cites the NIS→USD conversion; F3 confirms the grant under the 2021 plan; F4 details vesting. Exhibit 24.1 (Power of Attorney) attached.

Context
This was an option grant (compensation/award), not a purchase or sale of shares — grants are routine director compensation and do not by themselves indicate buying or selling pressure. The options give Recanati the right to buy shares at NIS 1.75 ($0.58) once they vest; no exercise or sale occurred per this filing. The Form 4 was filed several weeks after the grant date, which is later than the usual two-business-day insider reporting requirement.